Generic Name: Trientine Hydrochloride
Brand Name: MAR-Trientine
Manufacturer: Marcan Pharmaceuticals Inc.
Therapeutic Area: Wilson's Disease
Indications: MAR-Trientine (trientine hydrochloride) is indicated for the treatment of patients with Wilson's Disease who are intolerant to penicillamine. MAR-Trientine should only be initiated by physicians experienced in the management of Wilson’s Disease.
Manufacturer Requested Reimbursement Criteria1: MAR-Trientine (trientine hydrochloride) to be reimbursed for the treatment of patients with Wilson's Disease who are intolerant to penicillamine.
Submission Type: Initial
Project Status: Pending
Call for patient/clinician input open: March 18, 2021
Call for patient/clinician input closed: May 7, 2021
Anticipated Date: April 19, 2021
Fee Schedule: Pending
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.